ASTRO: SABR Offers Long-Term Benefits Comparable to Surgery for Non-Small Cell Lung Cancer
For patients with non-small cell lung cancer, stereotactic ablative radiotherapy (SABR) offers long-term survival outcomes comparable to surgery.
A study presented at the annual meeting of the American Society for Radiation Oncology found that SABR provides long-term benefits similar to surgery for non-small cell lung cancer (NSCLC).
- 80 patients were treated with SABR.
- A matched cohort of 80 patients underwent video-assisted thoracoscopic lobectomy with mediastinal lymph node dissection.
Participants were followed for a median of 8.3 years, and the researchers found that:
- 11 percent of the patients undergoing surgery had occult lymph node involvement discovered on surgical pathology.
- 14 percent received adjuvant therapy.
No direct quote available in the text.
Author's summary: SABR offers comparable long-term benefits to surgery for NSCLC patients.
More News
- Uncovering untold stories: Finding Lucinda » Sandpoint Reader
- Electric Island Expands with Five Shows and a Massive Lineup
- Daily Joke: A drunken husband meets the devil… or does he?
- Wesleyan women blank Wheeling in 3-0 road win
- Mateusz Gamrot Releases His First Statement Following His Loss To Charles Oliveira
- ONLY ON 13: Relatives of family killed by drunk driver call for action
- Who won fashion month SS26 on social media?
- Liverpool battling with Tottenham & Man Utd to sign Fofana
- What Arkansas interim football coach Bobby Petrino said on his radio show ahead of Texas A&M game | Whole Hog Sports
- Armonico Consort and Baroque Players to perform series of classics